Next Article in Journal
The Accuracy of Distal Clavicle Fracture Classifications—Do We Need an Amendment to Imaging Modalities or Fracture Typing?
Previous Article in Journal
Increased Macrophage-like Cell Density in Retinal Vein Occlusion as Characterized by en Face Optical Coherence Tomography
Previous Article in Special Issue
Low Doses of Celecoxib Might Promote Phenotype Switching in Cutaneous Melanoma Treated with Dabrafenib—Preliminary Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 19
10.3390/jcm11195637
Review Report
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Drivers of Radioresistance in Prostate Cancer

J. Clin. Med. 2022, 11(19), 5637; https://doi.org/10.3390/jcm11195637
by Liam King 1,2, Nijole Bernaitis 1, David Christie 1,3,4, Russ Chess-Williams 4, Donna Sellers 4, Catherine McDermott 4, Wendy Dare 2 and Shailendra Anoopkumar-Dukie 1,*
Reviewer 2:
Michael Pinkawa
J. Clin. Med. 2022, 11(19), 5637; https://doi.org/10.3390/jcm11195637
Submission received: 22 August 2022 / Revised: 15 September 2022 / Accepted: 22 September 2022 / Published: 24 September 2022
(This article belongs to the Special Issue Novel Drug Targets for Cancer Management)

Round 1

Reviewer 1 Report

Interesting topic for this review paper.

Comprehensive review of resistance pathways.

I felt that the Conclusion is an anti climax

There is more scope to expand on targetable mechanisms of resistance 

No real mention of attempts to overcome resistance 

It would be topical to offer solutions to this challenge 

 

Author Response

Please attached response

Author Response File: Author Response.docx

Reviewer 2 Report

The topic of this study is of significant relevance in oncological practice.

Major points: 

It is important to explain the methods used for the study. Selection of studies? How have studies been selected.

As this is a journal of clinical medicine, I recommend to clearly separate the available studies into a) radiobiological studies and b) clinical studies.

For example: What are studies that show us that aniandrogen treatment combined with radiotherapy improves survival? Which studies show that castration resistant cancers are resistant to radiotherapy?

Minor point:

line 31 - androgen deprivation therapy is not a curative treatment as monotherapy

Author Response

Please see attached response

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

Thank you for the revisions.

There are a lot of clinical studies, including randomized studies, for antiandrogens in combination with radiotherapy. Furthermore, several clinical studies with new generation antiandrogens have also been published. They are routinely applied in clinical practice. Thus, the section on clinical applications need to be revised and these clinical studies mentioned and discussed.

In Table 1, several "currently approved inhibitors" have been listed. To avoid misunderstandings, please state which drugs have been approved for prostate cancer and who has approved these drugs.

Author Response

Please see attachment

Author Response File: Author Response.docx

Round 3

Reviewer 2 Report

The manuscript is acceptable for publication following the last revision.

Back to TopTop